QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
Urologists at the University of Texas Health and MD Anderson Cancer Center, San Antonio conducted a pilot study involving 29 men aged 30 to 80 years with a new prostate cancer diagnosis scheduled to undergo radical prostatectomy. They randomly assigned…
Dr. Ravi B. Parikh and his team, from the University of Pennsylvania Perelman School of Medicine, reported that the overall survival disparity between Black and White men may be due to decreased benefits associated with abiraterone treatment in White men. …
Researchers investigated whether statin use was associated with the outcomes of a randomized PSA- based prostate cancer screening trial. Data was used from a Finnish population-based study of prostate cancer screening that randomized men to PSA screening or routine care….
Decreases in PSA testing followed the 2012 USPSTF grade D recommendation on PSA testing and have been associated with increasing proportions of higher-stage disease and increasing incidence of metastatic disease. In April 2017, the US Preventive Services Task Force (USPSTF)…
Investigators suggested that the higher spatial resolution of MRI versus molecular PET imaging allows for more precise localization of local recurrence in the prostatectomy bed for salvage radiation or focal ablation. Eight hundred ninety-six patients with PSA of 0.2ng/mL or…
The risk for both all-cause and cancer-specific death increased for cancer survivors with the combination of prolonged sitting and inactivity. The combination of prolonged sitting and a lack of physical activity increases the risk for death among cancer survivors, according…
Dr. Catalona’s multi-institutional collaborative research team’s SPORE project results were highlighted in Prostate Cancer Advisor, Oct. 2021. The key results, first reported in The Journal of Urology, were that men with high-volume Gleason Grade Group 1 tumors behaved similarly to…
December 23, 2021, marked the 50th anniversary of the signing of the National Cancer Act which increased funding for cancer research and education and improved cancer treatment, benefitting patients today. The National Cancer Act was signed into law in 1971,…
BREAKING NEWS 2022 New research suggests that adding darolutamide to androgen deprivation therapy (ADT) and docetaxel improves overall survival for patients with metastatic hormone-sensitive prostate cancer (mHSPC), compared with ADT plus docetaxel alone. In addition, darolutamide significantly delayed the development…
The pre-PSA era Prostate cancer is the leading cause of non-skin cancer in men (26% of new cancer diagnoses) and the second-leading cause of cancer death (11% of cancer deaths in men). In the period between 1930 and 1985, the…
"*" indicates required fields
